Should I buy or sell Geron stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Geron in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" GERN shares. View GERN analyst ratings or view top-rated stocks .

What is Geron's stock price target for 2024?

3 equities research analysts have issued 1 year price objectives for Geron's stock. Their GERN share price targets range from $5.00 to $6.00. On average, they predict the company's share price to reach $5.33 in the next twelve months. This suggests a possible upside of 54.6% from the stock's current price. View analysts price targets for GERN or view top-rated stocks among Wall Street analysts .

How have GERN shares performed in 2024?

Geron's stock was trading at $2.11 on January 1st, 2024. Since then, GERN shares have increased by 63.5% and is now trading at $3.45. View the best growth stocks for 2024 here .

Are investors shorting Geron?

Geron saw a drop in short interest in the month of March. As of March 31st, there was short interest totaling 46,660,000 shares, a drop of 8.4% from the March 15th total of 50,950,000 shares. Based on an average daily volume of 11,240,000 shares, the days-to-cover ratio is currently 4.2 days. View Geron's Short Interest .

When is Geron's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our GERN earnings forecast .

How were Geron's earnings last quarter?

Geron Co. (NASDAQ:GERN) posted its earnings results on Wednesday, February, 28th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.01. The biopharmaceutical company earned $0.02 million during the quarter, compared to analyst estimates of $0.06 million. Geron had a negative net margin of 77,691.14% and a negative trailing twelve-month return on equity of 63.33%. The firm's revenue was down 77.7% on a year-over-year basis. During the same period in the previous year, the company earned ($0.10) earnings per share.

What ETFs hold Geron's stock?

ETFs with the largest weight of Geron (NASDAQ:GERN) stock in their portfolio include Invesco Pharmaceuticals ETF (PJP) , WisdomTree BioRevolution Fund (WDNA) , ALPS Medical Breakthroughs ETF (SBIO) , Range Cancer Therapeutics ETF (CNCR) , Virtus LifeSci Biotech Clinical Trials ETF (BBC) and Invesco Nasdaq Future Gen 200 ETF (QQQS) . Direxion Daily S&P Biotech Bull 3x Shares (LABU) .

What is John A. Scarlett's approval rating as Geron's CEO?

5 employees have rated Geron Chief Executive Officer John A. Scarlett on Glassdoor.com . John A. Scarlett has an approval rating of 82% among the company's employees.

What other stocks do shareholders of Geron own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Geron investors own include Novavax (NVAX) , Dynavax Technologies (DVAX) , Matinas BioPharma (MTNB) , Sorrento Therapeutics (SRNE) , ADMA Biologics (ADMA) , Rigel Pharmaceuticals (RIGL) , Chesapeake Energy (CHKAQ) , Organigram (OGI) , SCYNEXIS (SCYX) and Bionano Genomics (BNGO) .

How do I buy shares of Geron?

Shares of GERN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:GERN

Geron (GERN) Stock Price, News & Analysis

→ Elon Musk’s ChatGPT Could Soon Mint New Millionaires (From InvestorPlace) (Ad)

Free GERN Stock Alerts

$3.45

-0.19 (-5.22%)

(As of 04/15/2024 ET)

Compare

Today's Range: $3.40
▼
$3.71
50-Day Range: $1.75
▼
$3.77
52-Week Range: $1.64
▼
$4.05

Volume: 11.91 million shs
Average Volume: 11.40 million shs
Market Capitalization: $1.89 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $5.33

Get Geron alerts:

Geron MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 54.6% Upside
$5.33 Price Target
Short Interest: Healthy
8.53% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -2.80
Upright™ Environmental Score
News Sentiment: 0.54
Based on 14 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.34) to ($0.14) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.60 out of 5 stars

Medical Sector

264th out of 929 stocks

Pharmaceutical Preparations Industry

116th out of 425 stocks

3.5

Analyst's Opinion

Consensus Rating
Geron has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Geron has only been the subject of 3 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
8.53% of the outstanding shares of Geron have been sold short.
Short Interest Ratio / Days to Cover
Geron has a short interest ratio ("days to cover") of 4.2.
Change versus previous month
Short interest in Geron has recently decreased by 8.42%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Geron does not currently pay a dividend.
Dividend Growth
Geron does not have a long track record of dividend growth.

1.3

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Geron has received a -35.24% net impact score from Upright. The largest negative impact of Geron in category "GHG emissions" is driven by its "Nonwoven fabric machines" and "Textile spinning machines" products. See details.
Environmental Sustainability
The Environmental Impact score for Geron is -2.80.

3.1

News and Social Media Coverage

News Sentiment
Geron has a news sentiment score of 0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.65 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 14 news articles for Geron this week, compared to 4 articles on an average week.
Search Interest
51 people have searched for GERN on MarketBeat in the last 30 days. This is an increase of 21% compared to the previous 30 days.
MarketBeat Follows
25 people have added Geron to their MarketBeat watchlist in the last 30 days. This is an increase of 32% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Geron insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 3.00% of the stock of Geron is held by insiders.
Percentage Held by Institutions
73.71% of the stock of Geron is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Geron are expected to grow in the coming year, from ($0.34) to ($0.14) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Geron is -10.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Geron is -10.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Geron has a P/B Ratio of 7.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

Elon Musk’s ChatGPT Could Soon Mint New Millionaires

Elon Musk made $180 million on PayPal… $47 Billion on SpaceX…and $94.2 Billion on Tesla. He’s about to shock the world again with his version of ChatGPT.

And you could go along for the ride if you make this one simple move.

About Geron Stock (NASDAQ:GERN)

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

GERN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

GERN Stock News Headlines

March 20, 2024 | marketbeat.com

Geron Stock Doubles After Imetelstat Receives FDA Panel Approval

Geron Inc. NASDAQ: GERN is a clinical-stage biotech in the medical sector focused on developing cell therapies to treat certain types of blood cancers and myeloid hematologic malignancies. Their lead drug is imetelstat, which blocks a protein called telomerase to treat specific blood cancers like myelofibrosis and myelodysplastic syndromes.

March 20, 2024 | marketbeat.com

Geron Stock Doubles After Imetelstat Receives FDA Panel Approval

Geron stock is up more than 92% after the company's flagship blood cancer therapy received approval from an FDA advisory panel

April 16, 2024 | InvestorPlace (Ad)

Nerd Investor Reveals Secret To Make Money With A.I.

He's doing something he's never done before. In ten years, this nerd investor has picked 210+ stocks that have gone up at least 100%.

April 13, 2024 | americanbankingnews.com

Geron (NASDAQ:GERN) Rating Reiterated by Needham & Company LLC

April 11, 2024 | seekingalpha.com

Considering The Merits Of A Gamble On Geron Corporation

April 11, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Geron Following Insightful Leadership Discussion and Promising Drug Development Progress

April 11, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Carl Zeiss Meditec (GB:0DHC), Geron (GERN) and Zur Rose Group AG (Six Swiss: CH:DOCM)

April 11, 2024 | finance.yahoo.com

Geron Corporation (NASDAQ:GERN) Is Expected To Breakeven In The Near Future

April 16, 2024 | InvestorPlace (Ad)

Nerd Investor Reveals Secret To Make Money With A.I.

He's doing something he's never done before. In ten years, this nerd investor has picked 210+ stocks that have gone up at least 100%.

April 11, 2024 | americanbankingnews.com

Geron (NASDAQ:GERN) Given Outperform Rating at Wedbush

April 3, 2024 | businesswire.com

Geron to Participate at Upcoming Investor Conferences in April

March 27, 2024 | finance.yahoo.com

GERN Mar 2024 3.500 put

March 19, 2024 | markets.businessinsider.com

Geron Announces Pricing Of $150 Mln Underwritten Offering Of Common Stock, Pre-Funded Warrants

March 19, 2024 | msn.com

Geron announces pricing of $150M underwritten offering

March 19, 2024 | finance.yahoo.com

Geron Corporation Announces Pricing of $150 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

March 18, 2024 | finance.yahoo.com

GERN240517C00003500 (GERN240517C00003500) Interactive Stock Chart - Yahoo Finance

March 18, 2024 | finance.yahoo.com

GERN240517P00003500 (GERN240517P00003500) Interactive Stock Chart - Yahoo Finance

March 16, 2024 | finance.yahoo.com

GERN Apr 2024 1.000 put

March 16, 2024 | finance.yahoo.com

GERN Apr 2024 1.500 call

March 16, 2024 | wsj.com

Geron Corp.

March 15, 2024 | finance.yahoo.com

MDGL Apr 2024 270.000 call

March 15, 2024 | markets.businessinsider.com

Stifel Nicolaus Reaffirms Their Buy Rating on Geron (GERN)

March 15, 2024 | msn.com

Geron’s stock soars 95% after FDA advisory panel votes in favor of blood-disorder drug

March 15, 2024 | investorplace.com

Why Is Geron (GERN) Stock Up 94% Today?

March 15, 2024 | msn.com

Biggest stock movers today: ADBE, GERN, and more

March 15, 2024 | seekingalpha.com

Geron: Advisory Nod Boosts Approval Odds, But Market Position Remains Hazy

March 15, 2024 | msn.com

Geron surges after FDA AdCom backing for lead drug

See More Headlines

Receive GERN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Geron and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/28/2024
Today: 4/15/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: Biotechnology
Current Symbol: NASDAQ:GERN
CUSIP: 37416310
CIK: 886744
Web: www.geron.com
Phone: (650) 473-7700
Fax: 650-473-7750
Employees: 141
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $5.33
High Stock Price Target: $6.00
Low Stock Price Target: $5.00
Potential Upside/Downside: +54.6%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.33)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-184,130,000.00
Net Margins: -77,691.14%
Pretax Margin: -77,690.72%
Return on Equity: -63.33%
Return on Assets: -44.71%

Debt

Debt-to-Equity Ratio: 0.14
Current Ratio: 3.16
Quick Ratio: 3.16

Sales & Book Value

Annual Sales: $240,000.00
Price / Sales: 7,861.26
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.46 per share
Price / Book: 7.50

Miscellaneous

Outstanding Shares: 546,870,000
Free Float: 530,468,000
Market Cap: $1.89 billion
Optionable: Optionable
Beta: 0.61

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

Dr. John A. Scarlett M.D. (Age 73)
Chairman of the Board, President & CEO
Comp: $1.53M
Dr. Andrew J. Grethlein Ph.D. (Age 60)
Executive VP & COO
Comp: $847.2k
Ms. Michelle J. Robertson (Age 56)
Executive VP, CFO, Treasurer and Principal Financial & Accounting Officer
Ms. Aron Feingold
Vice President of Investor Relations & Corporate Communications
Mr. Scott Samuels
Executive VP, Chief Legal Officer & Corporate Secretary
Ms. Shannon Odam (Age 49)
Senior VP & Chief People Officer
Ms. Melissa A. Kelly Behrs (Age 60)
Executive VP of Business Operations & Chief Alliance Officer
Comp: $753.22k
Mr. Anil Kapur (Age 53)
Executive VP of Corporate Strategy & Chief Commercial Officer
Comp: $654.89k
Mr. Edward E. Koval (Age 62)
Executive VP & Chief Business Officer
Dr. Faye Feller M.D. (Age 41)
Executive VP & Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

GERN Stock Analysis - Frequently Asked Questions

Should I buy or sell Geron stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Geron in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" GERN shares.
View GERN analyst ratings or view top-rated stocks.
What is Geron's stock price target for 2024?: 3 equities research analysts have issued 1 year price objectives for Geron's stock. Their GERN share price targets range from $5.00 to $6.00. On average, they predict the company's share price to reach $5.33 in the next twelve months. This suggests a possible upside of 54.6% from the stock's current price.
View analysts price targets for GERN or view top-rated stocks among Wall Street analysts.
How have GERN shares performed in 2024?: Geron's stock was trading at $2.11 on January 1st, 2024. Since then, GERN shares have increased by 63.5% and is now trading at $3.45.
View the best growth stocks for 2024 here.
Are investors shorting Geron?: Geron saw a drop in short interest in the month of March. As of March 31st, there was short interest totaling 46,660,000 shares, a drop of 8.4% from the March 15th total of 50,950,000 shares. Based on an average daily volume of 11,240,000 shares, the days-to-cover ratio is currently 4.2 days.
View Geron's Short Interest.
When is Geron's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our GERN earnings forecast.
How were Geron's earnings last quarter?: Geron Co. (NASDAQ:GERN) posted its earnings results on Wednesday, February, 28th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.01. The biopharmaceutical company earned $0.02 million during the quarter, compared to analyst estimates of $0.06 million. Geron had a negative net margin of 77,691.14% and a negative trailing twelve-month return on equity of 63.33%. The firm's revenue was down 77.7% on a year-over-year basis. During the same period in the previous year, the company earned ($0.10) earnings per share.

What ETFs hold Geron's stock?: ETFs with the largest weight of Geron (NASDAQ:GERN) stock in their portfolio include Invesco Pharmaceuticals ETF (PJP), WisdomTree BioRevolution Fund (WDNA), ALPS Medical Breakthroughs ETF (SBIO), Range Cancer Therapeutics ETF (CNCR), Virtus LifeSci Biotech Clinical Trials ETF (BBC) and Invesco Nasdaq Future Gen 200 ETF (QQQS).Direxion Daily S&P Biotech Bull 3x Shares (LABU).
What is John A. Scarlett's approval rating as Geron's CEO?: 5 employees have rated Geron Chief Executive Officer John A. Scarlett on Glassdoor.com. John A. Scarlett has an approval rating of 82% among the company's employees.
What other stocks do shareholders of Geron own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Geron investors own include Novavax (NVAX), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), Rigel Pharmaceuticals (RIGL), Chesapeake Energy (CHKAQ), Organigram (OGI), SCYNEXIS (SCYX) and Bionano Genomics (BNGO).
How do I buy shares of Geron?: Shares of GERN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:GERN) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Geron (GERN) Stock Price, News & Analysis

Geron MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Geron Stock (NASDAQ:GERN)

GERN Stock Price History

GERN Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

GERN Stock Analysis - Frequently Asked Questions

Overall MarketRank^™